ES2144440T3 - Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen. - Google Patents

Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen.

Info

Publication number
ES2144440T3
ES2144440T3 ES93202428T ES93202428T ES2144440T3 ES 2144440 T3 ES2144440 T3 ES 2144440T3 ES 93202428 T ES93202428 T ES 93202428T ES 93202428 T ES93202428 T ES 93202428T ES 2144440 T3 ES2144440 T3 ES 2144440T3
Authority
ES
Spain
Prior art keywords
monoclonal antibody
receptor
egf
tumor cells
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93202428T
Other languages
English (en)
Inventor
Ndez Ordonez Alicia Calle Fern
De Acosta Del Rio Cristi Mateo
Abraham Amparo Emilia C Macias
Perez Pedro Pablo Macineira
Bravo Blanca Rosa Tormo
Rodriguez Rolando Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Immunologia Molecular
Original Assignee
Centro de Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU1992100A external-priority patent/CU22387A1/es
Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular
Application granted granted Critical
Publication of ES2144440T3 publication Critical patent/ES2144440T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UN ANTICUERPO MONOCLONAL QUE RECONOCE EL RECEPTOR DE FACTOR DE CRECIMIENTO EPIDERMICO (EGF), ES CAPAZ DE INHIBIR EGF QUE SE ENLAZA AL RECEPTOR, ES CAPAZ DE INHIBIR EL CRECIMIENTO DE CELULAS DE TUMOR DEPENDIENTE DE EGF, Y ADEMAS TIENE AL MENOS UNA DE LAS SIGUIENTES PROPIEDAD: A) TIENE CITOTOXICIDAD CELULAR DEPENDIENTE DE LOS ANTICUERPOS, B) TIENE ACTIVIDAD CITOTOXICA MEDIADORA DE COMPLEMENTO, C) ES CAPAZ DE PRODUCIR UN EFECTO SINERGETICO EN LA PROLIFERACION DE INHIBICION DE CELULAS DE TUMORES SI SE COMBINA CON UN ANTICUERPO MONOCLONAL CONTRA EGF,, O UN DERIVADO DE DICHO ANTICUERPO MONOCLONAL ELEGIDO ENTRE FORMAS HUMANIZADAS, QUIMERICAS REFORMADAS, BIESPECIFICAS, CONJUGADAS Y ANTIIDIOTIPICAS DE ESTE. O UN FRAGMENTO DE DICHO ANTICUERPO MONOCLONAL DE DICHO DERIVADO ELEGIDO ENTRE FRAGMENTOS DE FV, FAB, FAB'' Y F(AB'')2 DE ESTE. UNA COMPOSICION QUE COMPRENDE DICHO ANTICUERPO MONOCLONAL, EN PARTICULAR UNA COMPOSICION FARMACEUTICA PARA SU USO EN UN TRATAMIENTO TERAPEUTICO O PROFILACTICO DE NEOPLASMASMALIGNOS O ENFERMEDADES PRENEOPLASTICAS. UN PROCESO PARA PREPARAR EL ANTICUERPO MONOCLONAL, SU USO Y UNA CELULA INMORTALIZADA QUE LO PRODUCE.
ES93202428T 1992-08-18 1993-08-18 Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen. Expired - Lifetime ES2144440T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU1992100A CU22387A1 (es) 1992-08-18 1992-08-18 Anticuerpos monoclonados que reconocen el receptor del factor de crecimiento epidermico. procedimiento de obtencion
CU1993017 1993-03-01

Publications (1)

Publication Number Publication Date
ES2144440T3 true ES2144440T3 (es) 2000-06-16

Family

ID=25746823

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93202428T Expired - Lifetime ES2144440T3 (es) 1992-08-18 1993-08-18 Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen.

Country Status (7)

Country Link
EP (1) EP0586002B1 (es)
AT (1) ATE188874T1 (es)
DE (1) DE69327620T2 (es)
DK (1) DK0586002T3 (es)
ES (1) ES2144440T3 (es)
GR (1) GR3033290T3 (es)
PT (1) PT586002E (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
EP0659439B1 (en) 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
GB9405046D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
ES2167391T3 (es) * 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
IT1277827B1 (it) * 1995-03-01 1997-11-12 Ministero Uni Ricerca Scient E Anticorpo monoclonale chimerico murino/umano o un suo frammento specifico per il recettore egf (egf-r)
EP0745612B1 (en) * 1995-05-26 2001-11-07 MERCK PATENT GmbH Anti-idiotypic antibodies which induce an immune response against epidermal growth factor receptor
ATE208403T1 (de) * 1995-05-26 2001-11-15 Merck Patent Gmbh Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1239701C (zh) * 2000-05-19 2006-02-01 梨树化学株式会社 抗表皮生长因子受体的人源化抗体
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002241922B2 (en) * 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
NZ530212A (en) 2001-06-13 2006-09-29 Genmab As An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2542152T3 (es) 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
PL3086814T3 (pl) 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
RU2751512C2 (ru) 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
RU2018102358A (ru) 2015-06-23 2019-07-25 Байер Фарма Акциенгезельшафт Нацеленные конъюгаты ksp ингибиторов
DK3328426T3 (da) 2015-07-27 2021-07-12 Innocimab Pte Ltd Behandling af patienter diagnosticeret med pankreatisk duktalt adenocarcinom under anvendelse af monoklonale antistoffer mod den epidermale vækstfaktorreceptor (egfr)
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
EP3902829A2 (en) 2018-12-26 2021-11-03 Innate Pharma Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies

Also Published As

Publication number Publication date
DE69327620D1 (de) 2000-02-24
DE69327620T2 (de) 2000-08-03
PT586002E (pt) 2000-07-31
DK0586002T3 (da) 2000-06-19
ATE188874T1 (de) 2000-02-15
EP0586002A3 (en) 1994-05-25
EP0586002A2 (en) 1994-03-09
GR3033290T3 (en) 2000-09-29
EP0586002B1 (en) 2000-01-19

Similar Documents

Publication Publication Date Title
ES2144440T3 (es) Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen.
JP6181089B2 (ja) 条件依存活性抗上皮細胞増殖因子受容体抗体およびその使用方法
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
PE20020972A1 (es) Anticuerpos recombinantes asociados a gangliosidos
HUP0101160A2 (hu) Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
CA2523449A1 (en) Recombinant antibodies and fragments which recognize n glycolil gm3 ganglioside and its use in diagnosis and treatment of tumours
BRPI0017590B8 (pt) conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
AU2308595A (en) Monoclonal antibodies against hiv-1 and vaccines made thereo f
BRPI0316779B1 (pt) anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
UA90480C2 (uk) Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
PL1684869T3 (pl) Sposoby leczenia nowotworów wywodzących się z limfocytów B
IL253497B2 (en) Formulations and methods related to universal glycoforms for enhanced antibody efficacy
FI104234B1 (fi) Menetelmä vasta-ainekonjugaattien valmistamiseksi neoplastisten sairauksien hoitoon
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
HUT43495A (en) Process for production and compound for treating of cancer and beningn tumor
DE19634159C1 (de) Induktion einer Tumorimmunität durch Injektion von Hybridzellen
Bernhard et al. Induction of tumor‐cell lysis by bi‐specific antibody recognizing ganglioside GD2 and T‐cell antigen CD3
ES2094170T3 (es) Procedimiento y producto para el tratamiento de enfermedades gastricas.
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
MX2025002233A (es) Anticuerpos humanizados contra nectina-4 y conjugados de farmacos de la misma
MX2025001456A (es) Conjugados de farmacos de anticuerpos anti pvr humanizados
Dippold et al. Functional Properties and Application of Ganglioside Antibodies to Patients with Malignant Melanoma
NZ766836A (en) Anti-claudin 18.2 antibodies and uses thereof

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 586002

Country of ref document: ES